Literature DB >> 34043448

Targeted Therapies in Older Adults With Solid Tumors.

Nicolò Matteo Luca Battisti1, Lore Decoster2, Grant R Williams3, Ravindran Kanesvaran4, Hans Wildiers5,6, Alistair Ring1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34043448      PMCID： PMC8260907          DOI： 10.1200/JCO.21.00132

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  97 in total

1.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Authors:  David Cunningham; Istvan Lang; Eugenio Marcuello; Vito Lorusso; Janja Ocvirk; Dong Bok Shin; Derek Jonker; Stuart Osborne; Niko Andre; Daniel Waterkamp; Mark P Saunders
Journal:  Lancet Oncol       Date:  2013-09-10       Impact factor: 41.316

Review 2.  Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020.

Authors:  Marine Gilabert; Pauline Ries; Brice Chanez; Simon Triby; Eric Francois; Astrid Lièvre; Frederique Rousseau
Journal:  J Geriatr Oncol       Date:  2020-05-23       Impact factor: 3.599

3.  Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.

Authors:  Lauren E Dockery; William P Tew; Kai Ding; Kathleen N Moore
Journal:  Gynecol Oncol       Date:  2017-10-14       Impact factor: 5.482

4.  Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience.

Authors:  Bulent Cetin; Mustafa Benekli; Faysal Dane; Cem Boruban; Mahmut Gumus; Berna Oksuzoglu; Mehmet A Kaplan; Gulnihal Tufan; Alper Sevinc; Ugur Coskun; Suleyman Buyukberber
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

5.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Authors:  Ghassan K Abou-Alfa; Tim Meyer; Ann-Lii Cheng; Anthony B El-Khoueiry; Lorenza Rimassa; Baek-Yeol Ryoo; Irfan Cicin; Philippe Merle; YenHsun Chen; Joong-Won Park; Jean-Frederic Blanc; Luigi Bolondi; Heinz-Josef Klümpen; Stephen L Chan; Vittorina Zagonel; Tiziana Pressiani; Min-Hee Ryu; Alan P Venook; Colin Hessel; Anne E Borgman-Hagey; Gisela Schwab; Robin K Kelley
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

6.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

7.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Authors:  Alice T Shaw; Todd M Bauer; Filippo de Marinis; Enriqueta Felip; Yasushi Goto; Geoffrey Liu; Julien Mazieres; Dong-Wan Kim; Tony Mok; Anna Polli; Holger Thurm; Anna M Calella; Gerson Peltz; Benjamin J Solomon
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

8.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Authors:  Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark Pegram
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

9.  First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.

Authors:  Kosuke Takahashi; Hiroshi Saito; Yoshinori Hasegawa; Masahiko Ando; Masashi Yamamoto; Eiji Kojima; Yasuteru Sugino; Tomoki Kimura; Fumio Nomura; Tomohiko Ogasawara; Joe Shindoh; Norio Yoshida; Ryujiro Suzuki
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-03       Impact factor: 3.333

10.  Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.

Authors:  Gabe S Sonke; Lowell L Hart; Mario Campone; Frans Erdkamp; Wolfgang Janni; Sunil Verma; Cristian Villanueva; Erik Jakobsen; Emilio Alba; Erik Wist; Anne M Favret; Thomas Bachelot; Roberto Hegg; Paul Wheatley-Price; Farida Souami; Santosh Sutradhar; Michelle Miller; Caroline Germa; Howard A Burris
Journal:  Breast Cancer Res Treat       Date:  2017-10-22       Impact factor: 4.872
View more
  1 in total

Review 1.  Small molecule inhibitors targeting the cancers.

Authors:  Gui-Hong Liu; Tao Chen; Xin Zhang; Xue-Lei Ma; Hua-Shan Shi
Journal:  MedComm (2020)       Date:  2022-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.